The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XLIX.d

Lupus - Lupus syndrome (see also Vd)

Publications

Stranks L, Chapman S

Anti-tumour necrosis factor-?-induced lupus in a patient receiving infliximab for sarcoidosis.

Respirology case reports 2022 Aug;10;e01006 — 2022 Aug — e01006

Arnaud L, Mertz P, Gavand PE, Martin T, Chasset F, Tebacher-Alt M, Lambert A, Muller C, Sibilia J, Lebrun-Vignes B, Salem JE

Drug-induced systemic lupus: revisiting the ever-changing spectrum of the disease using the WHO pharmacovigilance database.

Annals of the rheumatic diseases 2019 04;78;504-508 — 2019 04 — 504-508

Magno Pereira V, Andrade C, Figueira R, Faria G, Jasmins L

Infliximab-Induced Lupus: A Case Report.

GE Portuguese journal of gastroenterology 2017 Mar;24;84-88 — 2017 Mar — 84-88

Jani M, Dixon WG, Kersley-Fleet L, Bruce IN, Chinoy H, Barton A, Lunt M, Watson K, , , Symmons DP, Hyrich KL

Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA.

RMD open 2017;3;e000314 — 2017 — e000314

Rosen DR, Cologne KG, Popek SM, Sung BC, Ortega AE, Senagore AJ

Recurrent drug-induced ANCA vasculitis in a patient with Crohn's colitis treated with infliximab: a potential contraindication to immunosuppressive therapy.

The American surgeon 2012 Dec;78;1406-8 — 2012 Dec — 1406-8

Hamzaoglu H, Cooper J, Alsahli M, Falchuk KR, Peppercorn MA, Farrell RJ

Safety of infliximab in Crohn's disease: a large single-center experience.

Inflammatory bowel diseases 2010 Dec;16;2109-16 — 2010 Dec — 2109-16

Nosbaum A, Goujon C, Fleury B, Guillot I, Nicolas JF, Bérard F

Arterial thrombosis with anti-phospholipid antibodies induced by infliximab.

European journal of dermatology : EJD 2007 Nov-Dec;17;546-7 — 2007 Nov-Dec — 546-7

Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN

Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials.

Arthritis and rheumatism 2000 Nov;43;2383-90 — 2000 Nov — 2383-90